Cellectis (CLLS) Total Current Liabilities (2013 - 2026)
Cellectis (CLLS) posted quarterly Total Current Liabilities of $134.5 million for Q1 2026, down 17.27% year-over-year from $162.6 million in Q1 2025, and down 7.72% quarter-over-quarter from $145.8 million in Q4 2025.
Cellectis (CLLS) Total Current Liabilities (2013 - 2026) Analysis & Trends
Cellectis' Total Current Liabilities history runs 14 years deep, the most recent figure standing at $134.5 million for Q1 2026.
- In Q1 2026, Total Current Liabilities fell 17.27% year-over-year to $134.5 million; the TTM figure through Mar 2026 stood at $134.5 million (down 17.27% YoY), while the FY2025 annual figure was $145.8 million, down 12.34% from the prior year.
- Total Current Liabilities for Q1 2026 stood at $134.5 million, down from $145.8 million in the prior quarter.
- The five-year high for Total Current Liabilities was $167.4 million in Q2 2025, with the low at $42.0 million in Q2 2023.
- The 5-year median for Total Current Liabilities is $145.8 million (2025), against an average of $111.9 million.
- The sharpest annual moves came in 2023 and 2024: Total Current Liabilities slipped 23.94% in 2023, then soared 279.65% in 2024.
- Cellectis' Total Current Liabilities stood at $48.1 million in 2022, then surged by 222.34% to $155.1 million in 2023, then rose by 7.17% to $166.3 million in 2024, then retreated by 12.34% to $145.8 million in 2025, then decreased by 7.72% to $134.5 million in 2026.
- Business Quant data shows CLLS's Total Current Liabilities at $134.5 million in Q1 2026, $145.8 million in Q4 2025, and $148.6 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 3.94 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 5.53 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.58 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 354.06 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 2.12 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 4.22 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 630.93 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 1.51 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 438.74 Mn |
| 10 | Cellectis | 306.61 Mn | 120.95 Mn | - | 134.50 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 134.50 Mn |
| Dec 31, 2025 | 145.75 Mn |
| Sep 30, 2025 | 148.58 Mn |
| Jun 30, 2025 | 167.43 Mn |
| Mar 31, 2025 | 162.57 Mn |
| Dec 31, 2024 | 166.27 Mn |
| Sep 30, 2024 | 165.65 Mn |
| Jun 30, 2024 | 159.63 Mn |
| Mar 31, 2024 | 158.45 Mn |
| Dec 31, 2023 | 155.14 Mn |
| Sep 30, 2023 | 43.95 Mn |
| Jun 30, 2023 | 42.05 Mn |
| Mar 31, 2023 | 43.14 Mn |
| Dec 31, 2022 | 48.13 Mn |
| Sep 30, 2022 | 53.03 Mn |
| Jun 30, 2022 | 55.28 Mn |
| Mar 31, 2022 | 52.34 Mn |
| Dec 31, 2021 | 49.35 Mn |
| Sep 30, 2021 | 49.60 Mn |
| Jun 30, 2021 | 51.45 Mn |